P. Trunet

发表

Letrozole (CGS 20267). A phase I study of a new potent oral aromatase inhibitor of breast cancer

R. Santen, L. Demers, A. Lipton, 1995, Cancer.

Choosing an antihypertensive combination with a more efficient central blood pressure reduction

S. Laurent, P. Boutouyrie, P. Trunet, 2010 .

Letrozole, a new oral non-steroidal aromastase inhibitor in treating postmenopausal patients with advanced breast cancer. A pilot study.

G. Cocconi, F. Fraschini, F. Scaglione, 1996, Annals of oncology : official journal of the European Society for Medical Oncology.

Clinical Trials in Paediatric Oncology

A. Baruchel, G. Vassal, S. Durrleman, 2003 .

Influence of age, previous health status, and severity of acute illness on outcome from intensive care

J. L. Gall, C. Brun-Buisson, M. Rapin, 1982, Critical care medicine.

Letrozole (CGS 20267), a new oral aromatase inhibitor for the treatment of advanced breast cancer in postmenopausal patients.

A. Bhatnagar, H. Chaudri, P. Trunet, 1996, Acta oncologica.

Influence of caloric intake on the respiratory mode during mandatory minute volume ventilation.

F. Lemaire, A. Harf, J. Bonnet, 1985, Chest.

Decreased plasma epinephrine concentrations after glucose ingestion in humans.

J. Ansquer, J. Tillement, F. Lhoste, 1984, Metabolism: clinical and experimental.

In vivo measurement of aromatase inhibition by letrozole (CGS 20267) in postmenopausal patients with breast cancer.

M. Dowsett, S. Johnston, I. Smith, 1995, Clinical cancer research : an official journal of the American Association for Cancer Research.

Endocrine changes with the aromatase inhibitor fadrozole hydrochloride in breast cancer.

T. Powles, M. Dowsett, R. Coombes, 1994, European journal of cancer.

Effect of omalizumab in health care workers with occupational latex allergy.

V. Le Gros, I. Bourdeix, F. Leynadier, 2004, The Journal of allergy and clinical immunology.

Letrozole: updated duration of response.

H. Chaudri, P. Trunet, 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Open dose-finding study of a new potent and selective nonsteroidal aromatase inhibitor, CGS 20 267, in healthy male subjects.

A. Bhatnagar, P. Mueller, P. Trunet, 1993, The Journal of clinical endocrinology and metabolism.

Phase I study of the oral nonsteroidal aromatase inhibitor CGS 20267 in healthy postmenopausal women.

M. Dowsett, I. Smith, D. Smithers, 1993, The Journal of clinical endocrinology and metabolism.

Computed tomography and post-laparotomy intra-abdominal abscesses

J. Carlet, J. R. Gall, N. Vasile, 1983, Intensive Care Medicine.

Haemolytic streptococcal gangrene and non-steroidal anti-inflammatory drugs.

C. Brun-Buisson, J. Roujeau, J. Revuz, 1985, British medical journal.

Clinical use of aromatase inhibitors in the treatment of advanced breast cancer

A. Bhatnagar, H. Chaudri, P. Trunet, 1997, The Journal of Steroid Biochemistry and Molecular Biology.

Original article: CGS 16949A, a new aromatase inhibitor in the treatment of breast cancer — A Phase I study

F. Cavalli, A. Bhatnagar, K. Hoeffken, 1990 .

The role of drug-induced illness in admissions to an intensive care unit

F. Lhoste, M. Rapin, I. Borda, 2004, Intensive Care Medicine.

Letrozole, a new oral aromatase inhibitor for advanced breast cancer: double-blind randomized trial showing a dose effect and improved efficacy and tolerability compared with megestrol acetate.

P. Dombernowsky, J. Bellmunt, T. Hatschek, 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Letrozole: which dose to be used?

A. Buzdar, H. Chaudri, P. Trunet, 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Inhibition of estrogen biosynthesis and its consequences on gonadotrophin secretion in the male

K. Schieweck, A. Bhatnagar, P. Müller, 1992, The Journal of Steroid Biochemistry and Molecular Biology.

Phase I study of the oral nonsteroidal aromatase inhibitor CGS 20267 in postmenopausal patients with advanced breast cancer.

M. Dowsett, I. Smith, D. Smithers, 1993, Cancer research.

The effects of fadrozole hydrochloride on aldosterone secretion in healthy male subjects.

J. Ménard, F. Girard, A. Bhatnagar, 1992, The Journal of clinical endocrinology and metabolism.

Amlodipine-Valsartan Combination Decreases Central Systolic Blood Pressure More Effectively Than the Amlodipine-Atenolol Combination: The EXPLOR Study

Stéphane Laurent, S. Laurent, P. Boutouyrie, 2010, Hypertension.

Pirprofen-induced fulminant hepatitis.

G. Danan, D. Pessayre, C. Degott, 1985, Gastroenterology.

Therapeutic effects of the aromatase inhibitor fadrozole hydrochloride in advanced breast cancer.

T. Powles, M. Dowsett, R. Coombes, 1996, British Journal of Cancer.

COMPARATIVE BIOAVAILABILITY OF LETROZOLE UNDER FED AND FASTING CONDITIONS IN 12 HEALTHY SUBJECTS AFTER A 2·5 MG SINGLE ORAL ADMINISTRATION

A. Sioufi, J. Godbillon, H. Howald, 1997, Biopharmaceutics & drug disposition.

The role of iatrogenic disease in admissions to intensive care.

J. Carlet, B. Régnier, J. L. Le Gall, 1980, JAMA.

Omalizumab-induced decrease of FcξRI expression in patients with severe allergic asthma.

M. Humbert, A. Didier, P. Chanez, 2010, Respiratory medicine.

CGS 16949A, a new aromatase inhibitor in the treatment of breast cancer--a phase I study.

F. Cavalli, A. Goldhirsch, A. Bhatnagar, 1990, Annals of oncology : official journal of the European Society for Medical Oncology.

Diagnostic features of early high post‐laparotomy fever: A prospective study of 100 patients

J. Meakins, J. Carlet, J. L. Le Gall, 1982, The British journal of surgery.

Phase I study in healthy male volunteers with the non-steroidal aromatase inhibitor CGS 20267

A. Bhatnagar, H. Chaudri, P. Müller, 1990 .